{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:29:04Z","timestamp":1793647744668,"version":"4.5.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,16]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Dementia-related adverse event (AE) reports represent an important area of concern in pharmacovigilance, particularly considering the clinical relevance of cognitive impairment and the complexity of medication use among older adults. This study aims to systematically characterize the reporting patterns of dementia-related AEs and detect disproportionality signals. Dementia-related AE reports in the Food and Drug Administration Adverse Event Reporting System database from the first quarter of 2004 to the first quarter of 2024 were analyzed using the reporting odds ratio and proportional reporting ratio methods. The reports were classified and organized at the Standardized Medical Dictionary for Regulatory Activities Queries and Preferred Term levels to explore the potential association strength between drug-associated dementia and the related drugs and drug categories. We identified a total of 33,772 AE reports related to dementia, with 1103 drugs reported as the main suspected drugs. Overall, immunosuppressants, psycholeptics, and antineoplastic agents were the most frequently reported drug categories. Among them, apixaban exhibited the highest number of AE reports, followed by pimavanserin and lenalidomide. Notably, psycholeptics represented the highest proportion of the top 30 drugs by AE report count. Disproportionality analysis showed that 191 and 135 drugs were associated with potential signals of dementia. This study provides a comprehensive overview of dementia-related AE reports from a pharmacovigilance perspective, offering pharmacovigilance signals that may inform further drug safety evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000051134","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:00:25Z","timestamp":1792173625000},"page":"e51134","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A FAERS pharmacovigilance analysis of dementia-related adverse event reports"],"prefix":"10.1097","volume":"105","author":[{"given":"Tiantian","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, West China Hospital Sichuan University Jintang Hospital, Jintang First People\u2019s Hospital, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China"},{"name":"Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China"},{"name":"Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Mao","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0559-2450","authenticated-orcid":false,"given":"Meiling","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4486-568X","authenticated-orcid":false,"given":"Xianbin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/17512433.2023.2211261","article-title":"Psychiatric and non-psychiatric drugs causing false-positive amphetamines urine test in psychiatric patients: a pharmacovigilance analysis using FAERS.","volume":"16","author":"Battini","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R2-20261102","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system.","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"R3-20261102","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bcp.15277","article-title":"Pharmacovigilance in China: evolution and future challenges.","volume":"89","author":"Song","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R4-20261102","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ncl.2022.05.001","article-title":"Management of psychiatric symptoms in dementia.","volume":"41","author":"Ayhan","year":"2023","journal-title":"Neurol Clin"},{"key":"R5-20261102","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3390\/genes14112048","article-title":"Pharmacogenomics of dementia: personalizing the treatment of cognitive and neuropsychiatric symptoms.","volume":"14","author":"Vuic","year":"2023","journal-title":"Genes"},{"key":"R6-20261102","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","article-title":"Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study.","volume":"5","author":"Jia","year":"2020","journal-title":"Lancet Public Health"},{"key":"R7-20261102","doi-asserted-by":"crossref","first-page":"e2215192120","DOI":"10.1073\/pnas.2215192120","article-title":"Elevated dementia risk, cognitive decline, and hippocampal atrophy in multisite chronic pain.","volume":"120","author":"Zhao","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-20261102","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/practneurol-2019-002335","article-title":"Exercise and dementia prevention.","volume":"20","author":"Alty","year":"2020","journal-title":"Pract Neurol"},{"key":"R9-20261102","doi-asserted-by":"crossref","first-page":"e038255","DOI":"10.1002\/alz.038255","article-title":"World Alzheimer report 2019: attitudes to dementia, a global survey: public health: engaging people in ADRD research.","volume":"16","author":"Lynch","year":"2020","journal-title":"Alzheimer\u2019s Dement"},{"key":"R10-20261102","doi-asserted-by":"crossref","first-page":"e0285305","DOI":"10.1371\/journal.pone.0285305","article-title":"The value of supportive care: a systematic review of cost-effectiveness of non-pharmacological interventions for dementia.","volume":"18","author":"Guzzon","year":"2023","journal-title":"PLoS One"},{"key":"R11-20261102","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5582\/bst.2022.01042","article-title":"The management of dementia worldwide: a review on policy practices, clinical guidelines, end-of-life care, and challenge along with aging population.","volume":"16","author":"Wang","year":"2022","journal-title":"Biosci Trends"},{"key":"R12-20261102","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019.","volume":"7","author":"Nichols","year":"2022","journal-title":"Lancet Public Health"},{"key":"R13-20261102","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.sapharm.2020.09.001","article-title":"Examining the dispensing patterns of antipsychotics in Australia from 2006 to 2018 \u2013 a pharmacoepidemiology study.","volume":"17","author":"Claassen","year":"2021","journal-title":"Res Soc Admin Pharm"},{"key":"R14-20261102","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/jgs.18711","article-title":"Disease latency and new-user versus prevalent-user cohort designs: implications for pharmacoepidemiology in dementia reply.","volume":"72","author":"Lee","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"R15-20261102","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00228-020-02871-7","article-title":"Drug prescriptions in nursing home residents: an Italian multicenter observational study.","volume":"76","author":"Pasina","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-20261102","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jad.2024.01.029","article-title":"Associations between antipsychotics exposure and dementia risk: a prospective cohort study of 415,100 participants.","volume":"349","author":"Ma","year":"2024","journal-title":"J Affect Disord"},{"key":"R17-20261102","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/2589977514666220301102717","article-title":"Antipsychotic medication risk of dementia and death: a propensity matched cohort study.","volume":"14","author":"Lowe","year":"2022","journal-title":"Curr Drug Res Rev"},{"key":"R18-20261102","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10654-020-00643-2","article-title":"Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes.","volume":"36","author":"Mueller","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"R19-20261102","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/jgs.17623","article-title":"Effect of antipsychotics on mortality risk in patients with dementia with and without comorbidities.","volume":"70","author":"Norgaard","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"R20-20261102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40266-022-00992-5","article-title":"Implications of adverse outcomes associated with antipsychotics in older patients with dementia: a 2011-2022 update.","volume":"40","author":"Rogowska","year":"2023","journal-title":"Drugs Aging"},{"key":"R21-20261102","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neubiorev.2021.04.031","article-title":"Anticholinergic drugs and the risk of dementia: a systematic review and meta-analysis.","volume":"127","author":"Zheng","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"R22-20261102","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4081\/reumatismo.2024.1547","article-title":"Rheumatic diseases in migrant patients resident in Tuscany: epidemiological data analysis and single-center experience.","volume":"76","author":"Cometi","year":"2024","journal-title":"Reumatismo"},{"key":"R23-20261102","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/ijms25053044","article-title":"Molecular mechanisms linking osteoarthritis and Alzheimer\u2019s disease: shared pathways, mechanisms and breakthrough prospects.","volume":"25","author":"Umoh","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R24-20261102","doi-asserted-by":"crossref","first-page":"1054246","DOI":"10.3389\/fimmu.2022.1054246","article-title":"Association between systemic rheumatic diseases and dementia risk: a meta-analysis.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R25-20261102","doi-asserted-by":"crossref","first-page":"105044","DOI":"10.1016\/j.jbspin.2020.06.017","article-title":"Reversible anti-TNF\u03b1 treatment induced dementia: a case report.","volume":"88","author":"Hou","year":"2021","journal-title":"Joint Bone Spine"},{"key":"R26-20261102","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5414\/CP204433","article-title":"Does methotrexate use increase the risk of dementia in patients with rheumatoid arthritis?","volume":"61","author":"Elahi","year":"2023","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R27-20261102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13195-020-00606-5","article-title":"Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study.","volume":"12","author":"Newby","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"R28-20261102","doi-asserted-by":"crossref","first-page":"e226567","DOI":"10.1001\/jamanetworkopen.2022.6567","article-title":"Comparative risk of Alzheimer disease and related dementia among medicare beneficiaries with rheumatoid arthritis treated with targeted disease-modifying antirheumatic agents.","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R29-20261102","doi-asserted-by":"crossref","first-page":"e004016","DOI":"10.1136\/rmdopen-2023-004016","article-title":"Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis.","volume":"10","author":"Xie","year":"2024","journal-title":"RMD Open"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:00:17Z","timestamp":1793646017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":29,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000051134","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"2026-06-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}